Summit Therapeutics receives an FDA CRL for ivonescimab after HARMONi Phase III showed significant PFS improvement but no significant OS benefit.
Written By: Siddhi Bhadekar, M. Pharm (QA)
Reviewed By: Pharmacally Editorial Team
Summit Therapeutics has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its Biologics License Application (BLA) seeking approval of ivonescimab, a PD-1 × VEGF bispecific antibody, in combination with platinum-containing chemotherapy for locally advanced or metastatic EGFR-mutated, non-squamous non-small cell lung cancer (NSCLC) following epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy. The company announced the decision on November 15, 2026, stating that the application cannot be approved in its present form.
According to Summit, the FDA determined that substantial evidence of effectiveness had not been established without a statistically significant improvement in overall survival (OS). The agency also indicated that a progression-free survival (PFS) benefit without a statistically significant OS improvement did not support a positive benefit-risk profile for approval. Summit noted that no FDA-approved regimen in this patient setting has demonstrated a statistically significant OS benefit. Although the primary HARMONi OS analysis showed a positive trend, it did not achieve statistical significance. A subsequent post-hoc analysis using longer follow-up reported an OS hazard ratio (HR) of 0.76 across the overall, Asian, and Western populations; however, these exploratory findings did not change the regulatory outcome. Summit has not disclosed a specific resubmission plan or a scheduled FDA meeting.
HARMONi Phase III Trial Demonstrated Significant PFS Improvement
The BLA was supported by HARMONi (NCT06396065), a global, randomized, double-blind Phase III trial comparing ivonescimab plus carboplatin and pemetrexed with placebo plus the same chemotherapy in 438 patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC following progression on a third-generation EGFR TKI. The study had dual primary endpoints of PFS and OS and was conducted across 114 cancer centers and hospitals in Asia, Europe, and North America.
HARMONi met its primary PFS endpoint, with a median PFS of 6.8 months in the ivonescimab arm compared with 4.4 months in the control arm (HR 0.52; 95% CI 0.41–0.66; p less than 0.0001). Key secondary endpoints also favored the ivonescimab combination, including an objective response rate (ORR) of 45% versus 34%. These findings, published in The Lancet Oncology in August 2026, established a statistically significant PFS improvement.
However, the primary OS analysis showed a positive trend without reaching statistical significance, with a median OS of 16.8 months versus 14.0 months (HR 0.79; 95% CI 0.62–1.01; p = 0.057). Summit subsequently reported more mature OS findings, including an HR of 0.76 across geographical populations in a post-hoc analysis, though confidence intervals continued to cross 1.0. These results remain exploratory and should not be interpreted as establishing a confirmed survival benefit.
Safety Profile and Ivonescimab’s Molecular Design
Summit described the HARMONi safety profile as manageable, with no new safety signals. In the primary analysis, Grade 3 or higher treatment-related adverse events (TRAEs) occurred in 50.0% of patients in the ivonescimab arm versus 42.2% in the control arm. TRAEs led to discontinuation in 16 patients (7.3%) receiving ivonescimab and 11 patients (5.0%) receiving placebo, while TRAE-related deaths occurred in four patients (1.8%) and five patients (2.3%), respectively. Class-specific VEGF-related toxicities—including hypertension (13.3%), proteinuria (13.8%), and Grade 3 or higher hemorrhage (less than 1%)—were low and clinically manageable.
Ivonescimab, developed by Akeso, combines PD-1 blockade with VEGF inhibition in a single tetravalent antibody. Summit describes its cooperative binding mechanism as producing higher PD-1 affinity in the presence of VEGF, with the molecular design intended to increase binding strength within the tumor microenvironment. These proposed characteristics represent the company’s description of the molecule rather than established regulatory findings.
The antibody is designated SMT112 in Summit’s licensing territories and AK112 elsewhere. It received its first marketing authorization in China in May 2024. According to Summit and Akeso, more than 5,000 patients have received ivonescimab in clinical studies, with over 100,000 additional patients treated commercially in China.
Expanded Clinical Development Beyond HARMONi
Despite the CRL, Summit stated that its commitment to ivonescimab development remains unchanged, citing five positive Phase III studies across Summit and Akeso. The company defines a positive study as one achieving statistical significance in at least one prespecified primary endpoint.
Beyond HARMONi, Summit is advancing several registrational and exploratory studies across solid tumors:
- Phase III trials: HARMONi-3 (evaluating ivonescimab plus chemotherapy in first-line squamous and non-squamous metastatic NSCLC), HARMONi-7 (evaluating ivonescimab monotherapy in first-line PD-L1–high metastatic NSCLC), and HARMONi-GI3 (in first-line unresectable metastatic colorectal cancer).
- Phase II/III and Phase II trials: HARMONi-GU1 (a Phase II/III study evaluating ivonescimab with enfortumab vedotin in urothelial carcinoma) and SMT112-216 (a Phase II study evaluating ivonescimab-based combinations in first-line metastatic clear-cell renal cell carcinoma).
- Collaborative studies: GORTEC 2024-04 ILLUMINE (Phase III in advanced head and neck squamous cell carcinoma) and ECOG-ACRIN EA2251 (Phase II/III in advanced biliary tract cancer). Summit is also developing combination programs with AstraZeneca, Daiichi Sankyo, Revolution Medicines, GSK, and Arcus Biosciences.
Clinical Interpretation
The CRL highlights the regulatory challenge of establishing clinical benefit through PFS improvement when a statistically significant OS advantage remains unproven. HARMONi demonstrated a substantial PFS improvement, but its primary OS analysis did not meet statistical significance. The subsequent post-hoc HR of 0.76 provides an encouraging exploratory signal without resolving that limitation.
The decision does not change U.S. clinical practice because ivonescimab remains unapproved in Summit’s licensing territories, including the United States and Europe. While its broader development program continues, the regulatory outcome underscores the importance of mature survival evidence in determining whether the observed PFS benefit can translate into an approvable benefit-risk profile.
Reference
Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application, Summit Therapeutics, 15 November 2026
Phase III Study of AK112 for NSCLC Patients, ClinicalTrials.gov ID NCT06396065
Le X et al, Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2026 Sep;27(9):1094-1109. doi: 10.1016/S1470-2045(26)00282-2
About the Writer
Siddhi Rajendra Bhadekar (Linkedin) is an M.Pharm professional with expertise in medical and scientific writing, literature review, publication writing, and evidence synthesis, supported by four peer-reviewed publications.
She brings working knowledge of ICH-GCP, MedDRA, pharmacovigilance, ADR/AE reporting, clinical data management, and regulatory documentation.
With experience across pharmaceutical R&D, Quality Control, and Quality Assurance, she combines scientific research skills with strong attention to accuracy and detail.
Her background in manuscript development, publication planning, and scientific communication enables her to translate complex healthcare information into clear, reliable content.
